stroke

Death Rates From Heart Disease And Stroke Could Be Significantly Less With These Drugs, Study Says
Death Rates From Heart Disease And Stroke Could Be Significantly Less With These Drugs, Study Says
Forbes
ESC 2018
stroke
heart disease
calcium channel blockers
statins
Flag link:
iSchemaView's RAPID Technology Now Installed in More Than 500 Stroke Centers
iSchemaView's RAPID Technology Now Installed in More Than 500 Stroke Centers
CP Wire
IschemiaView
stroke
devices
RAPID platform
Flag link:
iSchemaView's RAPID Technology Now Installed in More Than 500 Stroke Centers
IschemiaView
stroke
Flag link:
Encouraging trial results for Daiichi anti-stroke therapy
Encouraging trial results for Daiichi anti-stroke therapy
The Pharma Letter
Daiichi Sankyo
Lixiana
edoxaban
clinical trials
atrial fibrilation
stroke
Flag link:
Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
CP Wire
Bristol-Myers Squibb
Janssen
Factor XIa
stroke
Flag link:
Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
Bristol-Myers Squibb
Janssen
Factor XIa
stroke
Flag link:
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Fierce Pharma
Amgen
Repatha
DTC ads
heart attack
stroke
Flag link:
Biogen to Discontinue Development of Stroke Drug After Early-Stage Trial Failure
Biogen to Discontinue Development of Stroke Drug After Early-Stage Trial Failure
Xtalks
Biogen
stroke
clinical trials
natalizumab
Flag link:
In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed
In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed
Endpoints
Bayer
JNJ
stroke
clinical trials
Xarelto
bloodthinners
Flag link:
Details on surprise Novartis heart drug success due Aug 27
Details on surprise Novartis heart drug success due Aug 27
Yahoo/Reuters
Novartis
canakinumab
heart attacks
stroke
Flag link:
Why Amgen's Success Was a Big Disappointment
Why Amgen's Success Was a Big Disappointment
Motley Fool
Amgen
Repatha
heart attacks
stroke
Flag link:
Amgen Drug Prevents Heart Attacks, Not Deaths, Disappointing Experts
Amgen Drug Prevents Heart Attacks, Not Deaths, Disappointing Experts
Forbes
Amgen
Repatha
heart attacks
stroke
clinical trials
Flag link:
Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study
Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study
Yahoo/Reuters
Amgen
Repatha
heart attack
stroke
LDL cholesterol
Flag link:
Many at risk for stroke don’t get anti-clotting drugs
Many at risk for stroke don’t get anti-clotting drugs
Reuters
stroke
atrial fibrillation
Pradaxa
Xarelto
Eliquis
bloodthinners
Flag link:
Trial miss derails Acorda's Ampyra plans
Trial miss derails Acorda's Ampyra plans
BioPharma Dive
Acorda Therapeutics
AMPYRA
stroke
Flag link:
Acorda Stroke Study Fails, Dampening Revenue Growth Plans
Acorda Stroke Study Fails, Dampening Revenue Growth Plans
TheStreet.com
Acorda Therapeutics
AMPYRA
stroke
Flag link:
FDA approves St.Jude device to prevent recurring strokes in some patients
FDA approves St.Jude device to prevent recurring strokes in some patients
Yahoo/Reuters
FDA
St. Jude Medical
stroke
amplatzer PFO occluder
devices
Flag link:
Merck scraps development of osteoporosis drug due to stroke risk
Merck scraps development of osteoporosis drug due to stroke risk
Yahoo/Reuters
Merck
osteoporosis
stroke
Odanacatib
Flag link:
Nico touts studies using BrainPath to treat hemorrhagic stroke
Nico touts studies using BrainPath to treat hemorrhagic stroke
Mass Device
Nico
BrainPath
stroke
hemorrhagic stroke
devices
Flag link:
AstraZeneca heart drug fails in key stroke trial
AstraZeneca heart drug fails in key stroke trial
Yahoo/Reuters
AstraZeneca
stroke
clinical trials
Brilinta
Flag link:

Pages